Arvin K. George, MD, presented “Transperineal vs Transrectal Biopsy Clinical Trials: Mo’ Data Mo’ Problems” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: George, Arvin K. “Transperineal vs Transrectal Biopsy Clinical Trials: Mo’ Data Mo’ Problems.” October, 2024. Accessed Jan 2025. https://grandroundsinurology.com/transperineal-vs-transrectal-biopsy-clinical-trials-mo-data-mo-problems/
Transperineal vs Transrectal Biopsy Clinical Trials: Mo’ Data Mo’ Problems – Summary
Arvin K. George, MD, delves into the nuances of prostate cancer biopsy techniques, focusing on the comparison between transperineal and transrectal approaches.
In this 14-minute presentation, Dr. George shares that transperineal and transrectal biopsies demonstrate equivalent cancer detection rates, particularly for clinically significant prostate cancer. However, some retrospective data suggest potential advantages of transperineal biopsy in specific anatomical areas, with notable studies emphasizing the reduced risk of infections with transperineal biopsy. Dr. George also discusses a decreased need for antibiotics and the use of local anesthesia in a transperineal approach.
Further, Dr. George reflects on the implications for clinical practice, antibiotic stewardship, and cost-effectiveness for transperineal and transrectal approaches. His talk provides a comprehensive synthesis of current evidence, encouraging a balanced and thoughtful approach to biopsy method selection.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Arvin George, MD, serves as Director of Prostate Cancer Programs and Associate Professor (PAR) of Urology at Johns Hopkins School of Medicine in Baltimore, Maryland. He is a urologic surgeon who specializes in the diagnosis and management of genitourinary cancers. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his urology residency at the Smith Institute for Urology at the Hofstra North Shore-LIJ School of Medicine. He remained there to complete his endourology fellowship in New York, gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. George’s research interests include minimally-invasive and image-guided treatments, functional prostate imaging, and focal therapy for prostate cancer. His research aims to identify appropriate use for imaging in diagnosis, risk stratification, and management of prostate cancer, including active surveillance and selection/treatment of patients with novel focal therapy modalities.
